CYSLTR1

Across TCGA pan-cancer cohorts, CYSLTR1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYSLTR1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher CYSLTR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYSLTR1 expression acts as an unfavorable survival marker.

CHOL, LUAD, and CESC are the cancer types where CYSLTR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.285	0.711	.017	10	view →
CESC	OS	Median	All	0.099	0.585	.049	6	view →
PRAD	DFS	Median	All	0.120	0.935	<.001	6	view →
COAD	DFS	Median	All	0.153	0.697	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYSLTR1–CHOL (OS)

Open the CHOL breakdown →